<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Adler, Caleb</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Armodafinil Shows Potential Benefit for Depressive Symptoms in Bipolar Disorder</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">Armodafinil 150 mg daily for 8 weeks as an adjuvant with mood stabilizers and/or antipsychotic drugs improved depressive symptoms associated with bipolar I disorder. The benefits, however, were not statistically significant compared with placebo. The findings of a multi-institutional, international, Phase 3, randomized, double-blind, placebo-controlled trial are discussed in this article [APA 2014 (poster NR6-038); NCT01305408].</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>